721959-71-3

Usage

Aldehyde derivative of pyridine

2-(benzyloxy)-4,6-dimethylpyridine-3-carbaldehyde is derived from pyridine, a six-membered aromatic heterocyclic compound containing nitrogen, by incorporating an aldehyde functional group.

Benzyl ether group

The presence of a benzyloxy group (-OCH2Ph) in the compound indicates that it has an ether linkage between the pyridine ring and a benzyl group.

Methyl substituents

Two methyl groups (-CH3) are attached to the pyridine ring at the 4th and 6th positions, contributing to the compound's structure and properties.

Potential applications in medicinal chemistry

Due to its structural features, 2-(benzyloxy)-4,6-dimethylpyridine-3-carbaldehyde may be suitable for use as a building block or intermediate in the synthesis of pharmaceutical compounds.

Value in organic chemistry and drug discovery research

The chemical structure and properties of 2-(benzyloxy)-4,6-dimethylpyridine-3-carbaldehyde make it a valuable tool for researchers working in the fields of organic chemistry and drug discovery.

Upstream product

• 53475-53-9 2-(benzyloxy)-4,6-dimethylpyridine-3-carbonitrile 
• 100-44-7 benzyl chloride 
• 769-28-8 2-hydroxy-4,6-dimethyl-3-carbonitrile 

Downstream Products

• 721959-68-8 2-benzyloxy-4,6-dimethylpyridin-3-yl-3-fluoro-4-methylphenyl methanol 
• 1616291-16-7 C₂₅H₂₃ClF₂N₂O₃ 
• 1616290-58-4 4-{[2-(benzyloxy)-4,6-dimethylpyridin-3-yl]methyl}-N,6-dimethyl-5-oxo-2,3,4,5-tetrahydro-1,4-benzoxazepine-7-carboxamide 
• 1616290-37-9 4-((2-benzyloxy-4,6-dimethylpyridin-3-yl)methyl)-6-chloro-7-methoxy-3,4-dihydrobenzo[f ][1,4]oxazepin-5(2H)-one 

Relevant academic research and scientific papers

1,5,7-TRISUBSTITUTED ISOQUINOLINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF IN MEDICINES

The present disclosure relates to 1,5,7-trisubstituted isoquinoline derivatives, their preparation and pharmaceutical use. In particular, the present disclosure discloses a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, and a preparation method and use thereof. The definitions of the groups in the formula can be found in the specification and claims.

INHIBITORS OF EZH2

The present invention relates to compounds that inhibit activity of the histone lysine methyltransferase, Enhancer of Zeste Homolog 2 (EZH2), pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, such as hematologic and solid tumors.

ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS

This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.

Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2H)-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors

A new enhancer of zeste homolog 2 (EZH2) inhibitor series comprising a substituted phenyl ring joined to a dimethylpyridone moiety via an amide linkage has been designed. A preferential amide torsion that improved the binding properties of the compounds was identified for this series via computational analysis. Cyclization of the amide linker resulted in a six-membered lactam analogue, compound 18. This transformation significantly improved the ligand efficiency/potency of the cyclized compound relative to its acyclic analogue. Additional optimization of the lactam-containing EZH2 inhibitors focused on lipophilic efficiency (LipE) improvement, which provided compound 31. Compound 31 displayed improved LipE and on-target potency in both biochemical and cellular readouts relative to compound 18. Inhibitor 31 also displayed robust in vivo antitumor growth activity and dose-dependent de-repression of EZH2 target genes.

ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS

This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homo log 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.

SUBSTITUTED DIHYDROISOQUINOLINONE COMPOUNDS

This invention relates to compounds of general formula (I) in which R1, R2, R3, R4, L, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

ARYL FUSED LACTAMS AS EZH2 MODULATORS

This invention relates to compounds of Formula (I) in which R1, R2, R3, R4, X and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

ARYL AND HETEROARYL FUSED LACTAMS

This invention relates to compounds of general formula (I) in which R1, R2, U, V, L, M, R5, m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

NITROGENOUS HETEROCYCLIC DERIVATIVE, MEDICINAL COMPOSITION CONTAINING THE SAME, MEDICINAL USE THEREOF AND INTERMEDIATE THEREFOR

The present invention is to provide a nitrogen-containing heterocyclic derivative represented by the general formula (I) or a pharmaceutically acceptable salt thereof, or a prodrug thereof, which exerts an excellent inhibitory activity in human SGLT2 and